BTA 0.00% 57.0¢ biota holdings limited

its been a long time coming, page-2

  1. 9,506 Posts.
    lightbulb Created with Sketch. 660
    Nice one forbes,

    You are right sometimes it looks like the message never comes across that Relenza is going to be the winner but slowly the news is getting thru.

    I believe that it will not take long before the wider public will become better informed about the tamiflu / relenza situation and the resistance that Tamiflu is now experiencing.

    Imho we are now close to a total wide spread re-rating of Relenza.

    The impact that this re-rating is carrying with it will have a tremendous impact on Biota and its shareprice imo.

    Do we have to wait for the Quaterly royalty announcement from GSK to confirm that sales of relenza are now skyrocketing or will the market act before this announcement???

    I am fully invested in BTA and have been saying before that the writing is on the wall with this company.

    Soon all will realise what a steal Biota was at the current price of under the $1.30 per share.

    And do not think that the big boys do now want to be part of this upside.
    Study the bot buying, the market dept of more then 2 million more sellers then buyers, and the fact that dispite those facts the SP moves up 7.17% !!!!!

    With todays trading there is much more happening then the naked eye is seeing....
    We are not the only ones who believe that BTA is excellent buying, some big boys want to be in it before the share price is going to bolt.

    The doomsdayers on this site could well be part and parcel of this manipulation, but at the end no manipulation will keep the share price down for long, no matter how sofisticated.

    I look forward to some real upside in the share price and believe we are not far from it.

    Please do your own research

    Good luck to ALL holders

    jojo
 
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.